FDA approves Perrigo and Teva’s generic nasal spray

ALLEGAN, Mich. The Food and Drug Administration has given final approval for the marketing of a generic version of an allergy drug.

Perrigo Co. and Teva Pharmaceutical Industries announced Monday that they had received approval for triamcinolone acetonide nasal spray, a generic version of Sanofi-Aventis’ Nasacort AQ.

The drug is used to treat seasonal and year-round allergies in patients aged 6 and older. Nasacort AQ had sales of about $305 million during the 12 months ending in June, according to Wolters Kluwer data.

Under the terms of a previous court settlement, Perrigo will manufacture and Teva will begin marketing their generic Nasacort AQ on June 15, 2011.